Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Liabilities and Shareholders Equity (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Liabilities and Shareholders Equity for 3 consecutive years, with $274.1 million as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Liabilities and Shareholders Equity fell 20.87% year-over-year to $274.1 million, compared with a TTM value of $875.3 million through Dec 2021, down 36.96%, and an annual FY2020 reading of $329.7 million, up 108.26% over the prior year.
  • Liabilities and Shareholders Equity was $274.1 million for Q3 2021 at Black Diamond Therapeutics, down from $287.9 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $362.8 million in Q1 2020 and bottomed at $158.3 million in Q4 2019.
  • Average Liabilities and Shareholders Equity over 3 years is $302.7 million, with a median of $321.5 million recorded in 2020.
  • The sharpest move saw Liabilities and Shareholders Equity skyrocketed 108.26% in 2020, then dropped 20.87% in 2021.
  • Year by year, Liabilities and Shareholders Equity stood at $158.3 million in 2019, then surged by 108.26% to $329.7 million in 2020, then decreased by 16.85% to $274.1 million in 2021.
  • Business Quant data shows Liabilities and Shareholders Equity for BDTX at $274.1 million in Q3 2021, $287.9 million in Q2 2021, and $313.3 million in Q1 2021.